As a result, M5049, a TLR7/8 inhibitor, is currently being tested in clinical trials for the treatment of severe symptoms of COVID-19 as a potential treatment for CRS (167) (Table 3). The gene discussed is TLR7; the disease is congenital rubella syndrome.